<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597557</url>
  </required_header>
  <id_info>
    <org_study_id>MED7441011B</org_study_id>
    <nct_id>NCT01597557</nct_id>
  </id_info>
  <brief_title>Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial</brief_title>
  <acronym>MICA</acronym>
  <official_title>Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium&#xD;
      sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the&#xD;
      energy threshold (in J) required for successful cardioversion of atrial fibrillation into&#xD;
      sinus rhythm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with atrial fibrillation may suffer from disabling symptoms such as palpitations,&#xD;
      shortness of breath or worsening heart failure. In such patients, it may be beneficial to&#xD;
      convert their rhythm to sinus rhythm. Cardioversion can be achieved either pharmacologically&#xD;
      or electrically. Pharmacological cardioversion is less successful acutely than electrical&#xD;
      cardioversion and may be associated with complications such as prolongation of the QT&#xD;
      interval and torsades de pointes (polymorphic ventricular tachycardia). Thus, cardioversion&#xD;
      is most often accomplished electrically, using biphasic synchronized shocks of 75-200 Joules.&#xD;
      Biphasic electrical cardioversion in atrial fibrillation has shown to be successful (i.e.,&#xD;
      converting to sinus rhythm) about 88% of the time, on average. The success rate appears to&#xD;
      largely depend upon the duration of the arrhythmia and the presence and severity of&#xD;
      structural heart disease.&#xD;
&#xD;
      In this study, we will evaluate the effect of intravenous magnesium sulfate on the success&#xD;
      rate of electrical cardioversion, and also assess its effect in decreasing the energy levels&#xD;
      needed for successful cardioversion. If the study is successful, we will have shown that a&#xD;
      simple and inexpensive intervention can increase the success rate of electrical&#xD;
      cardioversion, increasing the proportion of patients who can be restored to sinus rhythm. In&#xD;
      addition, success with lower energy levels may improve the safety of cardioversion, as high&#xD;
      energy levels are more likely to be associated with side effects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm</measure>
    <time_frame>One hour after cardioversion</time_frame>
    <description>Successful cardioversion involves conversion of atrial fibrillation to sinus rhythm and maintenance of sinus rhythm for one hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Energy Required for Successful Cardioversion of the Atrial Fibrillation to Sinus Rhythm</measure>
    <time_frame>One hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Severe Hypotensive Episodes After Infusion of Magnesium Sulfate or Placebo</measure>
    <time_frame>30 minutes</time_frame>
    <description>Severe hypotensive episode with a Systolic BP &lt; 90mm hg with &gt; 20 mm Hg drop after infusion of the study drug or placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>2 grams intravenous drip over 30 minutes</description>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline 50 ml intravenous drip over 30 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with new onset Atrial fibrillation less than 48 hours after onset undergoing&#xD;
             electrical cardioversion.&#xD;
&#xD;
          -  Patients with atrial fibrillation longer than 48 hours on warfarin with documented&#xD;
             therapeutic INR levels &gt;2 for at least 3 weeks prior to the cardioversion, or been on&#xD;
             dabigatran for 3 weeks, or a transesophageal echocardiogram on the day of the&#xD;
             procedure that excludes intracardiac thrombi, undergoing electrical cardioversion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine &gt;2.0 mg/dl&#xD;
&#xD;
          -  Potassium level less than 3.5 mmol/dl&#xD;
&#xD;
          -  TSH &lt; 0.5&#xD;
&#xD;
          -  Magnesium levels &gt;3.0 mg/dl&#xD;
&#xD;
          -  Urgent need for cardioversion (e.g., hemodynamic instability, unstable angina,&#xD;
             pulmonary edema)&#xD;
&#xD;
          -  Patients with recent (less than 6 weeks) acute myocardial infarction&#xD;
&#xD;
          -  Patients post-cardiac surgery&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients who are being treated with antiarrhythmic drugs who have received less than&#xD;
             five doses of the drug. For amiodarone, patients who have received less than three&#xD;
             weeks prior to cardioversion are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne B Curtis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bharath Rajagopalan, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne B Curtis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State University of New York at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <results_first_submitted>September 13, 2019</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Anne Curtis</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Electrical Cardioversion</keyword>
  <keyword>Magnesium Sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Some patients enrolled in the study and received the study drug but did not undergo the cardioversion procedure due to various reasons</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Magnesium Sulfate</title>
          <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure&#xD;
Magnesium Sulfate: 2 grams intravenous drip over 30 minutes</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure&#xD;
Placebo: Normal Saline 50 ml intravenous drip over 30 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not undergo cardioversion procedure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnesium Sulfate</title>
          <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure&#xD;
Magnesium Sulfate: 2 grams intravenous drip over 30 minutes</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure&#xD;
Placebo: Normal Saline 50 ml intravenous drip over 30 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
            <count group_id="B2" value="129"/>
            <count group_id="B3" value="261"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="10.4"/>
                    <measurement group_id="B2" value="65.6" spread="11.9"/>
                    <measurement group_id="B3" value="65.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm</title>
        <description>Successful cardioversion involves conversion of atrial fibrillation to sinus rhythm and maintenance of sinus rhythm for one hour</description>
        <time_frame>One hour after cardioversion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure&#xD;
Magnesium Sulfate: 2 grams intravenous drip over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure&#xD;
Placebo: Normal Saline 50 ml intravenous drip over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm</title>
          <description>Successful cardioversion involves conversion of atrial fibrillation to sinus rhythm and maintenance of sinus rhythm for one hour</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Energy Required for Successful Cardioversion of the Atrial Fibrillation to Sinus Rhythm</title>
        <time_frame>One hour</time_frame>
        <population>Some patients enrolled in the study and received the study drug but did not undergo the cardioversion procedure per protocol and were excluded in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure&#xD;
Magnesium Sulfate: 2 grams intravenous drip over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure&#xD;
Placebo: Normal Saline 50 ml intravenous drip over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Energy Required for Successful Cardioversion of the Atrial Fibrillation to Sinus Rhythm</title>
          <population>Some patients enrolled in the study and received the study drug but did not undergo the cardioversion procedure per protocol and were excluded in this analysis</population>
          <units>Joules</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.3" spread="55.5"/>
                    <measurement group_id="O2" value="129.5" spread="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Severe Hypotensive Episodes After Infusion of Magnesium Sulfate or Placebo</title>
        <description>Severe hypotensive episode with a Systolic BP &lt; 90mm hg with &gt; 20 mm Hg drop after infusion of the study drug or placebo</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure&#xD;
Magnesium Sulfate: 2 grams intravenous drip over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure&#xD;
Placebo: Normal Saline 50 ml intravenous drip over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Severe Hypotensive Episodes After Infusion of Magnesium Sulfate or Placebo</title>
          <description>Severe hypotensive episode with a Systolic BP &lt; 90mm hg with &gt; 20 mm Hg drop after infusion of the study drug or placebo</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Magnesium Sulfate</title>
          <description>Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure&#xD;
Magnesium Sulfate: 2 grams intravenous drip over 30 minutes</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients in this arm receive normal saline drip intravenously before the cardioversion procedure&#xD;
Placebo: Normal Saline 50 ml intravenous drip over 30 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Very few patients in paroxysmal AF, majority failed earlier rhythm control strategies making the study population a resistant population to treat, only one dose of Mg infusion was tested and the monitoring period was only 1 hour post cardioversion</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Anne Curtis</name_or_title>
      <organization>University at Buffalo</organization>
      <phone>716-859-4828</phone>
      <email>abcurtis@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

